- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals Inc stock price live, this page displays NYSE ATNM stock exchange data. View the ATNM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Actinium Pharmaceuticals Inc real time stock price chart below.
What Is the Actinium Pharmaceuticals Inc Stock Price Today?
The Actinium Pharmaceuticals Inc stock price today is 1.650.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc?
The stock symbol for Actinium Pharmaceuticals Inc is ""ATNM.""
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATNM quote. (ISIN: US00507W2061)
What Is the Actinium Pharmaceuticals Inc Stock Price Today?
The Actinium Pharmaceuticals Inc stock price today is 1.650.
What Is the Stock Symbol for Actinium Pharmaceuticals Inc?
The stock symbol for Actinium Pharmaceuticals Inc is ""ATNM.""
What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?
Actinium Pharmaceuticals Inc is listed and trades on the NYSE stock exchange.
Is Actinium Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Actinium Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATNM quote. (ISIN: US00507W2061)
Fair Value
An estimate of a Actinium Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.530
1.650
52 wk Range
1.029
2.410
ATNM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
1/2
Fair Value
An estimate of a Actinium Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5301.650
52 wk Range
1.0292.410
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATNM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Actinium Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
5.000
Upside
+203.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Actinium Pharmaceuticals Inc Company Profile
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Actinium Pharmaceuticals Inc SWOT Analysis
Iomab-ACT's Potential | Actinium's flagship product, Iomab-ACT, shows promise in targeted cancer therapies and bone marrow transplant conditioning, with recent FDA clearance for sickle cell disease |
Market Expansion | Delve into Actinium's strategic move into the sickle cell disease market, potentially addressing 100,000 U.S. patients annually and positioning for gene therapy applications |
Financial Discipline | Explore how Actinium's efficient cost management and lower-than-expected operating expenses are extending its runway and enhancing flexibility in clinical program pursuits |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $21 to $50, reflecting optimism about Actinium's innovative approach in targeted radiotherapies |
Compare ATNM to Peers and Sector
Metrics to compare | ATNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −3.2x | −0.5x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price/Book | 2.7x | 2.6x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | 212.5% | 194.0% | 40.3% | |
Fair Value Upside | Unlock | 5.3% | 4.7% | Unlock |
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.000
(+203.03% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.22 / -0.348
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Actinium Pharmaceuticals Trade On?
Actinium Pharmaceuticals is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Actinium Pharmaceuticals?
The stock symbol for Actinium Pharmaceuticals is "ATNM."
What Is the Actinium Pharmaceuticals Market Cap?
As of today, Actinium Pharmaceuticals market cap is 51.16M.
What Is Actinium Pharmaceuticals's Earnings Per Share (TTM)?
The Actinium Pharmaceuticals EPS (TTM) is -1.32.
When Is the Next Actinium Pharmaceuticals Earnings Date?
Actinium Pharmaceuticals will release its next earnings report on 13 Aug 2025.
From a Technical Analysis Perspective, Is ATNM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Actinium Pharmaceuticals Stock Split?
Actinium Pharmaceuticals has split 1 times.
How Many Employees Does Actinium Pharmaceuticals Have?
Actinium Pharmaceuticals has 27 employees.
What is the current trading status of Actinium Pharmaceuticals (ATNM)?
As of 14 Aug 2025, Actinium Pharmaceuticals (ATNM) is trading at a price of 1.65, with a previous close of 1.60. The stock has fluctuated within a day range of 1.53 to 1.65, while its 52-week range spans from 1.03 to 2.41.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.